Roswell Park Cancer Institute: Adenocarcinoma trials

The registry lists 12 Adenocarcinoma studies with Roswell Park Cancer Institute as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 5Phase 2 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) AdenocarcinomaCompletedNCT04097028Phase 2Results posted
• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
• Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal CancerCompletedNCT02393755Phase 1/2Results posted
• Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction CancerCompletedNCT01178944Phase 2Results posted
• Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous TreatmentCompletedNCT00942266Phase 2Results posted
• Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing ObservationCompletedNCT00887432Not applicableResults posted
• Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal AdenocarcinomaTerminatedNCT00625183Phase 2Results posted
• FL118 for Treating Patients With Advanced Pancreatic Ductal AdenocarcinomaWithdrawnNCT06206876Phase 1
• Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerWithdrawnNCT04119830Phase 2
• Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic CancerWithdrawnNCT02575508Phase 1/2
• Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's EsophagusCompletedNCT01238042Phase 1
• Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine HydrochlorideCompletedNCT00981162Phase 1